World
AstraZeneca Drug Combination Extends Lung Cancer Survival
Source: Mychesco|
1 min read
WILMINGTON, DE — AstraZeneca’s IMFINZI combined with Amgen’s tarlatamab-dlle extended median survival to 21.1 months in patients with extensive-stage small cell lung cancer, compared with 12.7 months for IMFINZI alone, …